D-0167-2023 Class III Terminated
FDA drug recall D-0167-2023 was initiated by Intersect ENT, Inc. on Jan 4, 2023 and is designated Class III. Reason for recall: Failed Dissolution Specification; product did not meet the average 24-hour drug release rate (dissolution) specification stability time point at 9 months. The recall status is terminated (terminated Aug 21, 2024). Affected quantity: 9898 pouches.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 25, 2023
- Initiation Date
- Jan 4, 2023
- Termination Date
- Aug 21, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 9898 pouches
Product description
SINUVA (mometasone furoate) sinus implant, 1350 mcg, 1 implant per pouch, Rx Only, intersect ENT, 1555 Adams Drive, Menlo Park, CA 94025, NDC 10599-003-01.
Reason for recall
Failed Dissolution Specification; product did not meet the average 24-hour drug release rate (dissolution) specification stability time point at 9 months.
Distribution pattern
Nationwide
Code information
Lot #s: 10111003, Exp 12/31/2022; 10203002, Exp 01/31/2023; 10302002, 10325001, Exp 02/28/2023; 10519001, 10526002, Exp 04/30/2023; 10602002, Exp 05/31/2023; 10819004, Exp 09/30/2023; 21092101, 21111901, Exp 10/31/2023; 21110402, Exp 12/31/2023.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0167-2023
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Intersect ENT, Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.